CLINICAL TRIALS PROFILE FOR HDM201
✉ Email this page to a colleague
Clinical Trials for HDM201
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02143635 ↗ | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | Completed | Novartis Pharmaceuticals | Phase 1 | To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53. |
NCT02295722 ↗ | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma | Unknown status | Tom Baker Cancer Centre | Phase 1/Phase 2 | Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell transplantation in patients with relapsed/refractory lymphoma. |
NCT02295722 ↗ | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma | Unknown status | AHS Cancer Control Alberta | Phase 1/Phase 2 | Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell transplantation in patients with relapsed/refractory lymphoma. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for HDM201
Condition Name
Clinical Trial Locations for HDM201
Trials by Country
Clinical Trial Progress for HDM201
Clinical Trial Phase
Clinical Trial Sponsors for HDM201
Sponsor Name